- Patient Education
“Dr. Sadiq is the only doctor in the US who is FDA approved to treat MS patients with stem cells. To me, the idea that my dad could feel better wasn’t even in the realm of possibility. . . My dad and I held hands as Dr. Sadiq explained what the stem cell treatments would entail over the next six months. Less than halfway through the conversation, my dad interrupted Dr. Sadiq, who was midsentence. ‘I have to pee.’ . . . The doctor continued while my dad was in the restroom, explaining that... more
By: Dr. James W. Stark
The European Committee for Treatment and Research in Multiple Sclerosis or ECTRIMS conference recently wrapped in London, England. ECTRIMS is a large international MS conference, which brings together hundreds of MS researchers, clinicians, and other health care professions to present and discuss the hottest topics in the field today. Much has come out of the conference including updates on several new disease modifying drugs, which have shown promise for both... more
Tisch MSRCNY is pleased to announce they have completed the treatment phase on all 20 patients participating in the stem cell trial! A full analysis of all of the results will be reviewed and presented at this year's Tisch MS Research Center 19th Annual MS Patient Symposium on October 16th, 2016 at The Hilton Midtown. In addition, these results will be submitted for publication in leading scientific journals.
Have you been told by your IMSMP neurologist that it's time for an MRI? Our state-of-the-art MRI Suite, located on the 3rd floor specializes in MS imaging. Call (212) 265-8070 to schedule your appointment and experience how MS healthcare should be!
Recently, Lancet Neurology published an article on the long-term follow up for a stem cell treatment on MS patients. This treatment involves high-dose chemotherapy to wipe out the immune system followed by stem cells to ‘reboot’ the immune system. The therapy has been studied for many years and is a very effective treatment for early, highly-aggressive, relapsing-remitting MS patients. However, safety issues persist and there are often other medications which can be used effectively in this... more
Dr. Saud A. Sadiq and researchers from the Tisch MS laboratory will present their work this week in San Francisco, CA at the ISSCR 2016 Annual Meeting. For a look at this year's event visit: http://www.isscr.org/home/annual-meeting/san-francisco-2016 We will have full updates of the research presented next week!
The FDA recently approved Zinbryta (daclizumab) for the treatment of adults with relapsing forms of multiple sclerosis. Zinbryta is a long-acting subcutaneous injection that is administered once a month. Zinbryta has shown efficacy in two large clinical trials, one of which compared this drug to Avonex. There are additional safety concerns with this medication, however, including possible damage to the liver. Patients on Zinbryta will have to perform blood tests to monitor liver function... more
The IMSMP is starting a new group for patients of the Center, who want to socialize and support one another yet may have difficulty traveling to the city. The group meets over the phone, once a month on Wednesdays. There are also openings to join the support group for newly diagnosed patients. For more information on either of these groups, please contact the Social Work Department at (212) 265-8070.